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Summary: This paper, the fourth in a series devoted to the study of the clinical usefulness of estimations of carcino-
embryonic antigen (CEA), describes CEA levels in extracts of metastatic breast tumours.
- Two groups can be distinguished, with CEA values higher or lower than 1.5 Mg CEA per g protein. The group of
tumours with a CEA level exceeding 1.5 Mg/g (CEA-positive) included a significantly larger percentage of oestrogen
receptor-positive tumours than the group with lower CEA levels (CEA-negative).
— It is stated that CEA-negative metastases are most likely to be found in patients who fail to respond to hormonal
therapy.
- No relation was demonstrable between the presence of androgen receptors and the CEA level. All the possible
permutations of CEA, oestrogen receptors and androgen receptors were encountered in the tumours examined.
Carcinoembryonale Antigene, Östrogenrezeptoren und Androgenrezeptoren beiMammatumoren des Menschen.
Klinische Bedeutung des carcinoembryonalen Antigens, IV.
Zusammenfassung: Diese vierte Arbeit einer Serie, die sich mit der klinischen Bedeutung der Bestimmung von
carcinoembryonalem Antigen (CEA) befaßt, beschreibt CEA-Werte in Extrakten von Metastasen von menschlichen
Mammatumoren. Die statistische Auswertung der Ergebnisse ergab zwei Gruppen mit einem Grenzwert von 1,5 % CEA
pro Gramm Eiweiß.
Eiri Vergleichsstudium bezüglich der Konzentrationen von Östrogen- und Androgenrezeptoren lieferte nachfolgende
Ergebnisse:
Die erste Gruppe, angedeutet als CEA negativ (mit CEA Werten unter 1,5 Mg/g) enthält einen wesentlich niedrigeren
Prozentsatz an Östrogenrezeptoren als die andere Gruppe. Hieraus ließ sich schließen, daß Patienten, bei denen die
hormonale Therapie einen ungünstigen Effekt hat, in den meisten Fällen CEA-negative Metastasen haben. Es wurde
gezeigt, daß die CEA-Bestimmung in Tumorextrakten die Messung der Östrogenrezeptoren für klinische Zwecke nicht
ersetzen kann.
Es wurde nachgewiesen, daß kein Zusammenhang zwischen dem Vorkommen von Androgenrezeptoren und den CEA-
Werten besteht. Offenbär besteht eine große Kombinationsmöglichkeit der obengenannten Substanzen in menschlichen
Mammatumoren.
Introduction The question which arises in this context is whether
determination of other parameters might lead to a more
It is now well established that patients suffering from detaued section of patients so that therapeutic effects
breast cancer with oestrogen receptor-positive metastases could be even Aore reiiabiy predicted,
have about a 60 percent chance of benefitting from
hormonal therapy, be it additive or ablative. In patients Wagner et al. (2) and Persijn et al. (3) determined the
with oestrogen receptor-negative metastases this chance occurrence of oestrogen receptor and androgen receptor
is low, but still about 10 percent (1). in 24 and 51 breast tumours, respectively. In some cases
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both receptors were present, in others one or the other
receptor was absent, and there were cases in which both
receptors were absent. Recently Wagner & Jungblut have
published a more detailed study of this subject (4).
Botet et al. (5) compared the results of oestrogen receptor
determinations in extracts of breast tumour tissue and of
normal mammary tissue with those of CEA assays in the
same extracts. They found an overall concordance of
about 60 percent between oestrogen receptor and CEA
in malignant specimens.
This paper presents the results of a study based on
determinations of oestrogen receptor, androgen receptor
and CEA in about 200 breast tumour tissue extracts.
Material and Methods
Assay of oestrogen receptors and androgen receptors
- Oestrogen receptors and CEA1) were measured in extracts of
100 benign and malignant tumours; in 80 of these androgen
receptors were also determined. In another series of 156 tumours,
both receptors were determined. The extracts were prepared as
described in reference (6). Portions of the extracts were used
immediately after preparation for receptor assays, while other
portions were kept frozen until used for CEA assays. Oestrogen
receptor and androgen receptor contents were measured by
electrophoresis according to Wagner (7). The classification of
receptor-negative and receptor-positive tumours was carried out
by probit analysis as described in references (8) and (9).
Tris buffer (8), standard inhibition curves obtained with Tris and
with PBS were compared. The two curves coincided completely.
The influence of tissue proteins present in extracts was also
studied. Standard inhibition curves with and without extract of
a benign breast tumour coincided completely.
- For assays of small quantities of CEA in tumour extract it is of
importance that the CEA used in the radio-immunoassay be free
from serum proteins. Experiments described in reference (10)
had already indicated that this is the case. In order to achieve
even greater certainty about possible contamination of 2SDI with
serum proteins, an experiment was carried out in which labelled
2SDI was incubated with horse anti-human serum antiserum.
Rabbit antihorse antiserum was added to precipitate the resulting
complex. As demonstrated in table 1, no significant binding of
labelled 2SDI to horse anti-human serum antiserum was found.
The reproducibility of the determination was tested against
results obtained with control solutions. For the solution with
4.4 jug/1 CEA, a standard deviation of 0.52 Mg/1 (n = 25) was
found; the standard deviation found for the solution with
9.6 Mg/1 was 0.99 Mg/1 (n = 25).
Results
Nearly equal percentages of oestrogen receptor and
androgen receptor were found in both primary and
metastatic breast tumours (tab. 2). The distribution shown
in table 3 reveals that all four combinations can be en-
countered. There are tumours which contain only
oestrogen receptor, only androgen receptor, or both, or
neither.
CEA assay in extracts of breast tumours
CEA assays in tumour extracts were carried out with the aid of
antiserum NKI-3 and CEA prepared by us (2SDI)1), the
properties of which have been described elsewhere (10).
In round-bottomed plastic tubes (length 4 cm, 0 8 mm), 50 μΐ
extract or standard CEA solution was mixed with 20 μΐ NKI-31),
diluted about 1:60,000 with phosphate-buffered saline containing
rabbit serum.
The mixture was incubated overnight at 37 °C, whereupon 20 μ!
[125 I]CEA (3 Mg/1) was added to each tube; incubation was
then continued for 5 hours at 37 °C. Antibody-bound CEA was
separated from unbound CEA using the double antibody
technique as described in reference (10).
For control, portions of two CEA solutions in Tris buffer (con-
taining about 4.7 and 9.6 Mg/1, respectively) were always included
in the series of samples. The compositions of the Tris buffer and
the phosphate-buffered saline are described in references (8) and
(10) respectively.
Evaluation of the CEA assay in extracts
The sample volumes available were too small for a duplicate CEA
assay as described in reference (10) (radio-immunoassay, system
2) as well as the analyses of the various receptors. The use of a
reduced sample volume necessitates alteration of the procedure
in order to ensure adequate sensitivity of the CEA assay.
Increased sensitivity was ensured by reducing the final volume of
the reaction mixture and the amount of anti-CEA antiserum
added.
Figure 1 shows a standard inhibition curve which is representative
for the curves obtained in our laboratory with NKI-3 in CEA
assays in extracts. Since the tissue extracts were prepared with
100
) Abbreviations:
CEA = carcino-embryonic antigen.
2SDI = CEA prepared by us.
NKI-3 = CEA antiserum.
20
25 6.3 1.6 0.4
Corcino- embryonic antigen lu.g/1]
Fig. 1. Standard inhibition curve.
Antiserum: NKI-3, diluted 1/60,000.
Tab. 1. Percentage of precipitated labelled 2SDI after incubation
with horse anti-human serum antiserum for 3 hours (37 °Q,
followed by incubation with rabbit anti-horse antiserum
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Tab. 2. Percentages of oestrogen receptor-positive or androgen
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Tab. 3. Distribution of oestrogen receptors and androgen
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The results of CEA assays in extracts of benign and
malignant tumours were classified according to probit
analysis. Malignant tumours were plotted in different
symbols, depending on their receptor positivity or
receptor negativity. This procedure provided an impres-
sion of the distribution of receptor-positive and receptor-
negative tumours over the various CEA content ranges of
these tumours (figs. 2 and 3).
Figure 2 shows the results in 100 tumour extracts with
reference to oestrogen receptors. The figure shows two
groups with different standard distribution curves. The
borderline CEA value seems to be approximately 1.5 Mg/g
protein. The group with CEA < 1.5 jug/g protein includes:
all benign tumours, which are oestrogen receptor-negative
(8,9) and 63.2% of the malignant tumours.
An evaluation of the distribution of oestrogen receptor-
positive and oestrogen receptor-negative tumours within
both groups, shows that 68.0% of the tumours in the
group with CEA > 1.5 μ^/g protein contained oestrogen
receptors; in the group with CEA < 1.5 μ^/g protein, only
32.5% of the malignant tumours contained oestrogen
receptors.
Figure 3 shows the results of CEA assays in extracts in
relation to androgen receptors in 90 tumours. Of the
benign tumours (all with < 1.5 /ig/g), 30% were androgen
receptor-positive, The group with < 1.5 //g/g included
65.5 % of the malignant tumours.
A relation between the presence of androgen receptor and
the CEA level in extracts of malignant breast tumours
was not demonstrable. The percentages of androgen
Carcino-embryonic antigen in the tumour extract
[M9/9 protein]
Fig. 2. Probit analysis of CEA quantities (Mg/g protein) determined
in benign (crosses) and malignant (circles) human breast
tumours. The solid circles represent oestrogen receptor-
positive tumours; the open circles oestrogen receptor-
negative tumours. Two receptor-positive and two receptor-
negative tumours with CEA content exceding 7 Mg/g are
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Carcino-embryonic antigen in the tumour extract
[M9/9 protein]
7.0
Fig. 3. Probit analysis of CEA quantities (Mg/g protein) determined
in benign (crosses) and malignant (circles) tumours. The
solid circles represent androgen receptor-positive tumours;
the open circles androgen receptor-negative tumours. Two
receptor-positive and two receptor-negative tumours with
CEA content exceding 7 μg/g are not inserted in the figure.
receptor-positive malignant tumours in both groups
(< 1.5 /zg/g and > 1.5 μΕ/g) were virtually equal: 57.9
and 55, respectively.
Discussion
The data so far presented warrant three conclusions.
1. The oestrogen receptor assay cannot be replaced by the
CEA assay in tumour extract.
2. Two groups of breast tumours can be distinguished:
one of largely oestrogen receptor-negative tumours
with a low CEA level, and one of largely oestrogen
receptor-positive tumours containing larger amounts
of CEA.
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3. Breast tumours vary widely with respect to the
presence of individual receptors, and the CEA level. In
fact, all possible permutations of CEA, oestrogen
receptor and androgen receptor can be encountered.
There are tumours which contain only oestrogen re-
ceptors or only androgen receptors, or only CEA, and
other tumours which contain some or all of these three
substances, or none of them.
The oestrogen receptor is an unstable substance, and a
considerable practical advantage would be gained if the
oestrogen receptor assay performed with a view to
therapeutic strategy in breast cancer patients could be
replaced by an assay of a more stable substance, e.g. CEA.
Botet et al. (5) cautiously concluded from their studies
that this would be impossible. Our results provide
strong evidence in favour of this conclusion. Figure 2
shows that definitely more than 10 percent of the
oestrogen receptor-negative metastases can be regarded
as CEA-positive. Without further clinical studies it can
therefore be maintained that CEA assay in tumour
extracts does not ensure a better selection of hormone-
unresponsive patients than can now be achieved by means
of the oestrogen receptor assay.
Better selection could perhaps be achieved by deter-
mination of more than one parameter. An indication to
this effect can be found in a report by Persijn et al. (3)
on androgen receptors in breast tumours. They supplied
evidence that determination of androgen receptor com-
bined with that of oestrogen receptor enhanced the
prediction of the effect of ovariectomy. Extensive further
clinical studies are required to establish whether CEA
assays combined with assays of receptors or other
,tumour markers' can significantly enhance the pre-
diction of therapeutic effects in some cases.
The second conclusion calls for some qualification. Since
about 90% of the oestrogen receptor-negative tumours
are hormone-unresponsive2), the second conclusion could
2) Clinically, a tumour is defined as hormone-responsive when-
ever hormonal therapy (be it additive or ablative) proves to be
effective. This term must not be confused with the adjective
»hormone-responsive* used in endocrinology with reference to
precisely those tissues that for their growth depend on the
presence of physiological concentrations of hormones in the
blood.
with some audacity be: hormone-unresponsive tumours
have a significantly higher incidence of low CEA levels
than hormone-responsive neoplasms. Gold & Freedman
(11) tried to explain the appearance of CEA during carcin-
ogenesis by postulating de-repression of previously
repressed genetic information, leading to resumption of
the synthesis of foetal antigens. They presented a detailed
discussion of two possible mechanisms of de-repression (11).
In view of the hypothesis of Gold & Freedman, our
finding could mean a relation between the hormone
responsiveness of a tumour and the type and degree of
de-repression underlying the development of the tumour.
If, on the other hand, we accept the theory of Collins &
Black (12), who hold that CEA is also present in normal
cells, as ,cryptic' antigen, then our finding implies that
hormone-responsive and hormone-unresponsive tumours
arise from different cell types.
The above-mentioned relation between hormone
responsiveness and CEA content assumes yet another
dimension in view of the results presented in figure 3.
This figure shows that there is no relation at all between
the presence of CEA and that of androgen receptors in
breast tumours. In this context we consider it of interest
to note that mainly metastases in postmenopausal women
were analysed in this study and that, in a previous report,
we supplied evidence that androgen receptors are not a
suitable parameter in predicting hormone responsiveness
in postmenopausal women (3).
In summary, we feel justified in maintaining that our
results may open a new avenue of understanding of the
complex phenomenon of hormone responsiveness of some,
and hormone unresponsiveness of other human breast
tumours.
Further studies on the diversity of receptors, antigens or
other 'tumour markers' in relation to therapeutic effects
and the ending of remissions are required.
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